CN101289666B - Method for preparing recombination porcine alpha-type interferon - Google Patents
Method for preparing recombination porcine alpha-type interferon Download PDFInfo
- Publication number
- CN101289666B CN101289666B CN2008100201804A CN200810020180A CN101289666B CN 101289666 B CN101289666 B CN 101289666B CN 2008100201804 A CN2008100201804 A CN 2008100201804A CN 200810020180 A CN200810020180 A CN 200810020180A CN 101289666 B CN101289666 B CN 101289666B
- Authority
- CN
- China
- Prior art keywords
- ifn
- bacterium
- alpha
- recombinant
- porcine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000005215 recombination Methods 0.000 title claims description 37
- 230000006798 recombination Effects 0.000 title claims description 37
- 229940079322 interferon Drugs 0.000 title claims description 31
- 108010050904 Interferons Proteins 0.000 title claims description 27
- 102000014150 Interferons Human genes 0.000 title claims description 27
- 238000000034 method Methods 0.000 title abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 55
- 239000013604 expression vector Substances 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 15
- 238000000746 purification Methods 0.000 claims abstract description 12
- 238000002474 experimental method Methods 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims description 58
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 31
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 31
- 230000029087 digestion Effects 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 230000000968 intestinal effect Effects 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 239000013612 plasmid Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 11
- 239000013599 cloning vector Substances 0.000 claims description 10
- 229910021529 ammonia Inorganic materials 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 9
- 238000010276 construction Methods 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 7
- 238000006386 neutralization reaction Methods 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 238000001042 affinity chromatography Methods 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000010186 staining Methods 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 239000000975 dye Substances 0.000 claims description 5
- 238000001962 electrophoresis Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000001742 protein purification Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 239000002699 waste material Substances 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 2
- 238000005336 cracking Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000002525 ultrasonication Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 28
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 206010012735 Diarrhoea Diseases 0.000 abstract description 7
- 238000004108 freeze drying Methods 0.000 abstract description 6
- 230000000840 anti-viral effect Effects 0.000 abstract description 5
- 206010022000 influenza Diseases 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 102000006992 Interferon-alpha Human genes 0.000 abstract 6
- 108010047761 Interferon-alpha Proteins 0.000 abstract 6
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 abstract 6
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 230000035876 healing Effects 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 244000144974 aquaculture Species 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101150103227 IFN gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a method for preparing porcine recombinant IFN-alpha. The method is to use a special primer - PCR to amplify target genes of the porcine IFN-alpha, to connect the target genes with an expression vector - pET-28a and an expression vector - pGEX-5X, to transform colon bacillus, to make the colon bacillus highly efficiently express the porcine IFN-alpha and to prepare porcine recombinant IFN-alpha freeze-dried injection through the techniques such as high purification, sterilization, split charging, freeze-drying and so on. The method is shown to have obvious treatment effect on porcine virus diarrhea, influenza and so on and be superior to similar products in the aspects of safety and cure rate through safety experiment, IFN efficacy inspection and clinic probation. The preparation technique is simple; industrialized production is easy; transportation and preservation are easy after freeze-drying. After the porcine recombinant IFN-alpha is injected into a porcine body, the porcine recombinant IFN-alpha is characterized by good healing effect, reliable assembly, no side effect like inocuity and so on, can be used for curing diseases like the porcine virus diarrhea, the influenza and so on, and is novel high-efficient safe nonpersistent broad-spectrum antiviral preparation.
Description
Technical field
The present invention relates to a kind of recombination porcine alpha-type interferon (interferon, method of production IFN) and process.System will have porcine alpha-type IFN gene recombination plasmid transformed into escherichia coli, and make it efficiently express porcine alpha-type IFN, and purified back adds the freeze-drying of an amount of porcine blood plasma albumin stablizer makes, and is used for the treatment of virus diseases such as pig virus diarrhoea and influenza.The standard of development and calibrating all adopts the recombination human alpha type IFN (the Chinese biological goods rules Chinese biological standard of articles council compiles 2000 editions) of national SFDA authentication also to implement as reference.
Background technology
The pig virus disease is the main transmissible disease that current serious restriction pig aquaculture develops in a healthy way.Generation is all arranged, as pig virus diarrhoea, influenza etc. the whole year.In case these animal infection morbidities then have onset anxious, clinical symptom is serious, very easily propagates diffusion, and case fatality rate and all higher characteristics of mortality ratio, causes the tremendous economic loss to aquaculture; What is more important, pig contacts closely with human, and some animal virus sexually transmitted disease is returned human health and is brought potential threat.Mainly be by vaccine inoculation and use microbiotic to pig virus prevention and treatment of diseases approach at present.But because breeding environment imperfection, reasons such as virus variation and Abwehrkraft des Koepers variation make traditional prevention and treatment approach be subjected to huge challenge, most of antibiotics and traditional oral antiviral, because the drug residue problem is brought negative impact to human health; And traditional vaccine because its high specific and side effect, can't be resisted the significant damage that the continuous appearance of virus variation and new virus brings for the pig aquaculture.Therefore, active treatment poultry, livestock disease viral disease will be the human problems of paying close attention to the most.
IFN be the infection induced body of a viroid produce have broad-spectrum antiviral, antitumor and have the protein of immunoregulation effect, nineteen fifty-seven Issacs and Lindeman at first find, it is the multi-functional cytokine of a class, after cell receptor combines, can induce body to produce multiple specific protein and enzyme, mainly by suppressing that virogene is transcribed and the viral RNA of degrading suppresses the growth and breeding of virus and bringing into play antitumor etc. activity.Generation cell, biochemical character according to IFN reach in the effect difference of being brought into play aspect the immunity of organism, are divided into α, β, γ three classes.Existing known, α type IFN can act on cells infecteds such as virus in vivo selectively, by the biosynthesizing of the intracellular virus protein that suppresses to be contaminted, performance wide spectrum and efficient disease-resistance toxic action.But normal host cell is not had effect or acts on faint.Pig IFN is that a class can induce pig cell to produce the proteic cytokine of multiple broad-spectrum antiviral, is mainly used in the control of virus diseases such as porcine epizootic diarrhea and swine influenza, and when particularly using with other cytokine is collaborative with pig, effect is better.Therefore, IFN is one of important biomolecule preparation that has a extensive future now.
At present, domestic that be applied to veterinary clinic the earliest is pig leucocyte IFN, but the white corpuscle IFN cost that adopts the isolating method of hemocyte to obtain is higher, and the blood source is easily contaminated, is difficult to carry out suitability for industrialized production.And adopt genetic engineering technique to produce recombination porcine alpha-type IFN except that can avoiding above-mentioned drawback, and the purity height is still arranged, cost is low, and advantage such as be produced on a large scale has vast market prospect.
Summary of the invention
The preparation method who the purpose of this invention is to provide a kind of recombination porcine alpha-type interferon, be with porcine alpha-type IFN gene recombination plasmid transformed into escherichia coli, make it efficiently express porcine alpha-type IFN, technologies such as purified back degerming, packing and freeze-drying are made, be a kind of broad-spectrum antiviral preparation, cure mainly virus diseases such as pig virus diarrhoea and influenza.
Technical solution of the present invention is as follows:
The preparation method of recombination porcine alpha-type interferon is characterized in that carrying out following steps:
(1), makes up cloning vector
Goal gene is:
TCACTCCTTCTTCCTGAGTCTGTCTTGCAGGTTTGTGGAGGAAGAGAAGGCTCTCATGACTTCTGCCCTGACGATCTCCCAGGCACAGGGGCTGTAGCTC TTCTCTTGCAGATAGAGGGTGAGTCTGTGGAAGTATTTCCTCACAGCCAGGATGGAGTCCTCCTCCAGCAGGGGGGTCCCTTCCAGCCCGGCCTCCTGC A TGACACAGGCTTCCAGGTCCCTGAGCTGCTGATCCAGTCCAGTGCAGAACTGGTGCAGGAGGCTCTCATCCCAGGCAGCAGCCGAGCCCTCTGTGCTG AA GAGCTGGAAGGTCTGCTGGAGCATCTCATGCACCAGAGCCATGGCTTGAGCCTTCTGGACCTGGTTGCCCCCCAAGGCCTCTTgGGGGAATCCAAAG TCC CTTCTGTGGTCCAGGCAGGAGAAGGGGGAGATTCTCCTCATTTGTGCCAGGAGCCTCAGGGCCCTGGTGTGAGCCAGGCTGTGGGTCTGAGGCAGG
Auele Specific Primer: upstream: GAATTC TGCGAC CTGCCT CAGACC CA
Downstream: CTCGAG TCACTC CTTCTT CCTGAG TC
Cloning vector: pMD18-T simple vector
(2), construction of expression vector
Expression vector: pET-28a, perhaps pGEX-5X
(3), Recombinant Protein Expression
The recombinant expressed bacterium of picking vector construction success is increased, amplification culture, and adds the expression of inductor low temperature induction;
(4), identify recombinant protein
Use anti-alpha-interferon reference serum and do the neutralization experiment, prove that type is errorless;
(5), purification of recombinant proteins, obtain the raw product Interferon, rabbit.
The preparation method of described recombination porcine alpha-type interferon is characterized in that concrete steps are:
(1), makes up cloning vector
Goal gene:
TCACTCCTTCTTCCTGAGTCTGTCTTGCAGGTTTGTGGAGGAAGAGAAGGCTCTCATGACTTCTGCCCTGAC
GATCTCCCAGGCACAGGGGCTGTAGCTCTTCTCTTGCAGATAGAGGGTGAGTCTGTGGAAGTATTTCCTCAC
AGCCAGGATGGAGTCCTCCTCCAGCAGGGGGGTCCCTTCCAGCCCGGCCTCCTGCATGACACAGGCTTCCAG
GTCCCTGAGCTGCTGATCCAGTCCAGTGCAGAACTGGTGCAGGAGGCTCTCATCCCAGGCAGCAGCCGAGCC
CTCTGTGCTGAAGAGCTGGAAGGTCTGCTGGAGCATCTCATGCACCAGAGCCATGGCTTGAGCCTTCTGGAC
CTGGTTGCCCCCCAAGGCCTCTTgGGGGAATCCAAAGTCCCTTCTGTGGTCCAGGCAGGAGAAGGGGGAGAT
TCTCCTCATTTGTGCCAGGAGCCTCAGGGCCCTGGTGTGAGCCAGGCTGTGGGTCTGAGGCAGGTCGCA
Specific primer sequence: upstream: GAATTC TGCGAC CTGCCT CAGACC CA
Downstream: CTCGAG TCACTC CTTCTT CCTGAG TC
Behind the goal gene with Auele Specific Primer pcr amplification porcine alpha-type interferon, with goal gene clone in pMD18-T simple vector to and transform the JM109 intestinal bacteria and be coated with the LB culture medium flat plate and carry out the screening of blue hickie, the clone bacterium of extracting waste sample carries out the target gene PCR checking, carries out double digestion simultaneously and identifies.According to experimental result, PCR and the equal positive plasmid of double digestion are carried out objective gene sequencing;
(2), construction of expression vector
After identifying that the back selects the clone bacterium consistent with goal gene to carry out double digestion, be connected, and correspondingly be converted into the BL-21 intestinal bacteria, cultivate respectively, identify the recombinant expressed bacterium of expression vector establishment success with expression vector pET-28a or pGEX-5X;
(3), Recombinant Protein Expression
The recombinant expressed bacterium that is connected with pET-28a or pGEX-5X expression vector of picking carries out a small amount of amplification, amplification culture respectively, adds isopropylthiogalactoside IPTG, and low temperature induction is expressed, and collects bacterium;
(4), identify recombinant protein
Use anti-alpha-interferon reference serum and do the neutralization experiment, prove that type is errorless;
(5), purification of recombinant proteins, obtain the raw product Interferon, rabbit.
The preparation method of described recombination porcine alpha-type interferon is characterized in that more detailed steps is:
(1), makes up cloning vector
The goal gene of porcine alpha-type IFN is:
TCACTCCTTCTTCCTGAGTCTGTCTTGCAGGTTTGTGGAGGAAGAGAAGGCTCTCATGACTTCTGCCCTGAC
GATCTCCCAGGCACAGGGGCTGTAGCTCTTCTCTTGCAGATAGAGGGTGAGTCTGTGGAAGTATTTCCTCAC
AGCCAGGATGGAGTCCTCCTCCAGCAGGGGGGTCCCTTCCAGCCCGGCCTCCTGCATGACACAGGCTTCCAG
GTCCCTGAGCTGCTGATCCAGTCCAGTGCAGAACTGGTGCAGGAGGCTCTCATCCCAGGCAGCAGCCGAGCC
CTCTGTGCTGAAGAGCTGGAAGGTCTGCTGGAGCATCTCATGCACCAGAGCCATGGCTTGAGCCTTCTGGAC
CTGGTTGCCCCCCAAGGCCTCTTgGGGGAATCCAAAGTCCCTTCTGTGGTCCAGGCAGGAGAAGGGGGAGAT
TCTCCTCATTTGTGCCAGGAGCCTCAGGGCCCTGGTGTGAGCCAGGCTGTGGGTCTGAGGCAGGTCGCA
Specific primer sequence: upstream: GAATTC TGCGAC CTGCCT CAGACC CA
Downstream: CTCGAG TCACTC CTTCTT CCTGAG TC
Behind the goal gene with Auele Specific Primer pcr amplification porcine alpha-type IFN, with goal gene clone in pMD18-Tsimple vector to and transform the JM109 intestinal bacteria and be coated with the LB culture medium flat plate and carry out the screening of blue hickie, the clone bacterium of extracting waste sample carries out the target gene PCR checking, carries out double digestion simultaneously and identifies.According to experimental result, PCR and the equal positive plasmid of double digestion are carried out objective gene sequencing;
(2), construction of expression vector
After identifying that the back selects the clone bacterium consistent with goal gene to carry out double digestion, be connected with expression vector pET-28a or pGEX-5X, and correspondingly be converted into the BL-21 intestinal bacteria, separate application is in the LB culture medium flat plate that contains kantlex or contain the LB culture medium flat plate overnight incubation of ammonia benzyl green grass or young crops, get the bacterium colony of growing on the aforementioned flat board and identify goal gene through PCR, the capable double digestion of positive colony bacteria plasmid is identified, is accredited as positive person and represents the expression vector establishment success;
(3), Recombinant Protein Expression
The recombinant expressed bacterium that is connected with pET-28a or pGEX-5X expression vector of picking is in the LB substratum that contains kantlex 100 μ g/ml or contain amplification on a small quantity in the LB substratum of the blue or green 100 μ g/ml of ammonia benzyl respectively, after respectively the LB substratum that contains kantlex 100 μ g/ml or contain in the LB substratum of the blue or green 100 μ g/ml of ammonia benzyl amplification culture or fermentation 3h after, to bacterium arrival logarithmic phase, survey bacterium in 600nm 0D value during at 0.6-0.8, add isopropylthiogalactoside IPTG, 32 ℃ of low temperature inductions are expressed, final concentration 200 μ g/ml collect bacterium;
(4), identify recombinant protein
Use anti-α type IFN reference serum and do the neutralization experiment, prove that type is errorless;
(5), purification of recombinant proteins, obtain raw product IFN.
The preparation method of described recombination porcine alpha-type interferon, it is characterized in that identifying recombinant protein: with the recombinant plasmid pET-28a/IFN and the pGEX-5X/IFN transformed into escherichia coli BL21 of goal gene, after IPTG induces, intestinal bacteria pET-28a/IFN tropina shows through SDS-PAGE protein electrophoresis and coomassie brilliant blue staining, compare with empty bacterium, a dense newly-increased protein band that dyes is arranged about 25KD; Intestinal bacteria pGEX-5X/IFN tropina shows through SDS-PAGE protein electrophoresis and coomassie brilliant blue staining, compares with empty bacterium, and a dense newly-increased protein band that dyes is arranged about 45KD.Identify through Western blotting, these two kinds of tropinas all can with anti-α type IFN reference serum generation strong positive reaction.
The preparation method of described recombination porcine alpha-type interferon is characterized in that purification of recombinant proteins is meant with behind the ultrasonication recombinant protein, obtains the solubility recombinant protein in the supernatant, again through AKTA
TMThe consummate albumen of explorer protein purification instrument affinity chromatography.
The preparation method of described recombination porcine alpha-type interferon, it is characterized in that: purification of recombinant proteins, the concrete steps that obtain raw product IFN are: collect bacterium liquid, 4 ℃ of centrifugal 5min of 12000r/min, abandon supernatant, stay precipitation ,-20 ℃ with room temperature multigelation precipitation 3 times after will precipitate mixing in 9 times of volume PBS liquid, hatch 5min for 4 ℃, ultrasonic degradation obtains recombinant protein, power: 400W, worked 3 seconds, 3 seconds at interval, ultrasonic 6min repeats 3-4 time, can make gram's staining and observe bacterium cracking situation, the centrifugal 10min of 12000r/min, the results supernatant.
The preparation method of described recombination porcine alpha-type interferon is characterized in that: AKTA
TMThe consummate albumen of explorer protein purification instrument affinity chromatography is measured IFN and is tired and specific activity specific activity 〉=1 * 10
6International unit/mg albumen is qualified; Aseptic subpackaged ,-70 ℃ of preservations.
The recombination porcine alpha-type interferon of the present invention's preparation after separation and purification, is made lyophilized injectable powder, after adding the 2ml aseptic double-distilled water, can be dissolved as even suspension liquid rapidly, specification is: IFN content 〉=20,000 unit/bottles, but 2～8 ℃ of prolonged preservation, room temperature (≤25 ℃) can be preserved 2 years.Can carry out intramuscular injection after will shaking up gently during use, piglet 5000～10,000 units/only/day; Grow up pig 20,000～40,000 units/only/day, inject once every day, course of treatment 3～5 times.
When treating the pig that fallen ill, should in time isolate the pig that do not fall ill, and give the protective inoculation of equivalent relative medicine, when using the recombination porcine alpha-type IFN of the present invention's preparation, should note the comprehensive prevention measures such as sterilization of environment, prevent and treat the recurrence of infection again or eqpidemic disease.
Embodiment:
Recombination porcine alpha-type IFN preparation technology flow process:
1. structure cloning vector:
Porcine alpha-type IFN goal gene is:
TCACTCCTTCTTCCTGAGTCTGTCTTGCAGGTTTGTGGAGGAAGAGAAGGCTCTCATGACTTCTGCCCTGAC
GATCTCCCAGGCACAGGGGCTGTAGCTCTTCTCTTGCAGATAGAGGGTGAGTCTGTGGAAGTATTTCCTCAC
AGCCAGGATGGAGTCCTCCTCCAGCAGGGGGGTCCCTTCCAGCCCGGCCTCCTGCATGACACAGGCTTCCAG
GTCCCTGAGCTGCTGATCCAGTCCAGTGCAGAACTGGTGCAGGAGGCTCTCATCCCAGGCAGCAGCCGAGCC
CTCTGTGCTGAAGAGCTGGAAGGTCTGCTGGAGCATCTCATGCACCAGAGCCATGGCTTGAGCCTTCTGGAC
CTGGTTGCCCCCCAAGGCCTCTTgGGGGAATCCAAAGTCCCTTCTGTGGTCCAGGCAGGAGAAGGGGGAGAT
TCTCCTCATTTGTGCCAGGAGCCTCAGGGCCCTGGTGTGAGCCAGGCTGTGGGTCTGAGGCAGGTCGCA
Specific primer sequence: upstream: GAATTC TGCGAC CTGCCT CAGACC CA
Downstream: CTCGAG TCACTC CTTCTT CCTGAG TC
Behind Auele Specific Primer pcr amplification porcine alpha-type IFN goal gene, with goal gene clone in pMD18-Tsimple vector to and transform the JM109 intestinal bacteria and be coated with the LB culture medium flat plate and carry out the screening of blue hickie, the clone bacterium of extracting waste sample carries out the target gene PCR checking, carries out double digestion simultaneously and identifies.According to experimental result, PCR and the equal positive plasmid of double digestion are carried out objective gene sequencing.
2. construction of expression vector:
Select goal gene cloning vector consistent after checking order to carry out behind the double digestion and be connected with expression vector pET-28a or pGEX-5X respectively with Genebank, and being converted into the BL-21 intestinal bacteria, separate application is in the LB culture medium flat plate that contains kantlex or contain the LB culture medium flat plate overnight incubation of ammonia benzyl green grass or young crops.Get the bacterium colony of growing on the LB flat board and identify goal gene through PCR, the capable double digestion of positive colony bacteria plasmid is identified, is accredited as positive person and represents the expression vector establishment success.
3. Recombinant Protein Expression:
The recombinant expressed bacterium that is connected with pET-28a or pGEX-5X expression vector of picking is in the LB substratum that contains kantlex 100 μ g/ml or contain amplification on a small quantity in the LB substratum of the blue or green 100 μ g/ml of ammonia benzyl respectively, after respectively in two kinds of LB substratum (contain kantlex 100 μ g/ml or contain the blue or green 100 μ g/ml of ammonia benzyl) behind the amplification culture or the 3h that ferments, survey the OD value when 0.6-0.8, add IPTG, 32 ℃ of low temperature inductions are expressed (final concentration 200 μ g/ml) 5h, collect bacterium.
For later on large-scale recombination porcine alpha-type IFN, need in fermentor tank, to express cultivation.The present invention has studied pilot scale fermentation technology simultaneously, and the expression level after the optimization reaches 50mg/L.
4. the preparation of raw product IFN:
Collect bacterium ,-20 ℃ with room temperature multigelation precipitation 3 times, 4 ℃ of ultrasonic degradation bacterial precipitations, power: 400W, work 3S, 3S at interval, ultrasonic 6min repeats 3-4 time, the centrifugal 15min acquisition of centrifugal 12000r/min supernatant.
5. raw product IFN purifying:
5.1AKTA
TMThe consummate albumen of explorer protein purification instrument affinity chromatography.
5.1.1 affinity chromatography:,, collect the IFN peak with Elution buffer (50mMTris-Cl 40mM reductive glutathione pH 8.0) gradient elution with crossing the GST affinity column after the rough albumen filtration treatment.
5.1.2 desalination, damping fluid displacement: the IFN of the first step purifying is crossed desalting column,, prepare next step ion exchange chromatography with damping fluid (50mMTris-ClpH6.5) displacement.
5.1.3 ion exchange chromatography: use the good cylinder of Loading buffer (50mMTri s-Cl pH6.5) balance respectively, with Elution buffer (50mMTris-Cl 1M NaCl pH6.5) gradient elution, collect the IFN peak behind the last sample.
5.1.4 sieve chromatography: the IFN that ion exchange chromatography is collected crosses molecular sieve chromatography, Elut ion buffer (50mMNa
2HPO
40.15MNaCl Ph7.0) collect I FN peak.
5.1.5 interpretation of result: detect purity of protein with SDS-page and westen behind each step purifying, Lowry method protein quantification calculates each step purifying yield.
Tire specific activity 〉=1 * 10 and specific activity 5.2 measure IFN
6International unit/mg albumen is qualified;
5.3 aseptic subpackaged ,-70 ℃ of preservations.
6. the evaluation of porcine alpha-type IFN behind the purifying:
6.1 protein quantification detects: use the Lowry method, do standard test with the standard protein of Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
6.2SDS-PAGE electrophoresis detection is compared with empty bacterium, two kinds of reorganization bacterium have a dense newly-increased protein band that dyes respectively about 25KD and 45KD.
6.3 the purity of recombinant porcine alpha IFN behind the efficient liquid phase chromatographic analysis purifying, pig α IFN＞95% behind the purifying.
6.4 western blot test: the sample behind the purifying can with anti-α type IFN reference serum generation strong positive reaction.
7. recombinant porcine alpha IFN tires and the mensuration of specific activity behind the purifying:
7.1IFN titration: recombinant porcine alpha IFN can suppress 100TCID behind the purifying on WISH cell
50The propagation of VSV virus.
7.1.1 on the trace Tissue Culture Plate of 96 holes, cultivate WISH cell, put 5%CO with the DMEM nutritive medium
2Cultivated 24 hours under 37 ℃ of conditions of incubator.
7.1.2 the pig α IFN with various dose handles.
Abandon 7.1.324 inhale after hour, inoculate 100TCID more respectively
50VSV virus.
7.1.4 the result shows that the cytopathy that the recombination porcine alpha-type IFN of acquisition causes VSV has the obvious suppression effect.Cell rounding all occurs after the undressed cell inoculation virus, come off, pathology such as disintegration.And after the cell inoculation virus after two kinds of recombinant porcine alpha IFN processing that obtain, under inverted microscope, observed seven days continuously, cellular form is normal, any pathology do not occur, record to tire＞10
7IU/ml.
7.2 specific activity measuring method: after the detection of the recombination porcine alpha-type IFN work in-process protein quantification behind the purifying, live＞1 * 10 with general in the world WISH/VZV systems measurement ratio
7IU/mg.
8. get supernatant liquor seitz filter pressure filtration, collect bacteria-free filtrate, steriling test and safety verification are carried out in sampling.After qualified after testing, add final concentration contain 5% skim-milk, 5%GS (glucose) and 10% porcine blood plasma albumin as the lyophilized vaccine mixing after, place the Freeze Drying Equipment freeze-drying.
9. recombination porcine alpha-type IFN suppresses the application in the pig parvoviral in porcine kidney cell:
9.1 on 96 holes trace Tissue Culture Plate,, put 5%CO with the DMEM nutrient solution culture nephrocyte (PK-15) of raising pigs
2Cultivated 24 hours under 37 ℃ of conditions of incubator.
9.2 recombination porcine alpha-type IFN function cells with various dose.
Abandon 9.324 inhale after hour, inoculate 100TCID more respectively
50The pig parvoviral suspension.
9.4 the result shows that the cytopathy that the recombination porcine alpha-type IFN of acquisition causes pig parvoviral has the obvious suppression effect.Cell rounding all occurs after the undressed cell inoculation virus, come off, pathology such as disintegration.And after the cell inoculation virus after the recombination porcine alpha-type IFN that the obtains processing, under inverted microscope, observed seven days continuously, cellular form is normal, any pathology do not occur.
10. recombination porcine alpha-type IFN safety experiment:
10.1 cavy check:
With 3 of the healthy guinea pigs of body weight 350～400g, each veutro subcutaneous injection recombination porcine alpha-type IFN 2ml observed 10, all strong living.
10.2 small white mouse check:
With 5 of the small white mouses of body weight 18～20g, each tail vein injection recombination porcine alpha-type IFN 0.5ml observed 7, all strong living.
10.3 suckling mouse check:
With 2 age in days suckling mouses, 1 nest (at least 5 are with female mouse to raise), every back subcutaneous injection 0.1ml establishes control group simultaneously, observes 7, all strong living.
10.4 pig check:
With 4 of the healthy susceptible weanling pigs that detects no swine fever maternal antibody through the neutralization test method (observed 5～7 before the injection, every day at the upper and lower noon is respectively surveyed body temperature 1 time, selects body temperature, spirit, the normal person's use of appetite).Every intramuscular injection finished product 6ml, inoculation back every day at the upper and lower noon respectively surveys body temperature and observes 1 time, observes 21.Compare before body temperature, spirit, appetite and injection this product and do not have considerable change; Or fervescence surpasses 0.5 ℃, but is no more than 1 ℃, delays to be no more than 2; Or subtract the food be no more than 1.Assay, sample are all qualified.
11. recombination porcine alpha-type IFN efficacy test:
Check with piglet:
According to " People's Republic of China's veterinary biologics rules " regulation, the test of selection is the weanling pig of healthy susceptible 21 ages in days with piglet, and every crowd of IFN injects 8.During test, each intramuscular injection IFN 20,000 U/ only (only is total to about 60,000 U/) for three days on end.24h after medication first, per os feeding pig parvoviral suspension (hemagglutinative titer 〉=1: 1280; TCID
50〉=1.0 * 10
-9/ ml) 0.1ml (200TCID
50).Establish simultaneously virus control group and normal control group equally.Attack poison back 12h, IFN protection group and all behaviors of normal control group test piglet are normal, and clinical symptom then appears in virus control group piglet.Cut open extremely after observing 96h, IFN protection group and normal control group intestinal tissue do not have obvious pathological change, and virus is separated negative; Obvious intestinal tissue pathological change then appears in the virus control group, and virus is separated positive.
12. clinical trial result:
The IFN of development in the Hefei City, Anhui Province, Duo Jia pig farms (family) such as Mingguang City and Wuhe County are on probation, the result proves that reorganization IFN is 86.5% to treating pig virus diarrhoea efficient, curative ratio is 67.9%; It is 88.53% that the treatment porcine parvovirus has rate, and curative ratio is 69.93%, and quality is better than existing products in markets.
＜110〉Wang Mingli
＜120〉preparation method of recombination porcine alpha-type interferon
<160>1
<210>1
<211>501
<212>DNA
＜213〉pig (Sus scrofa)
<220>
<221>CDS
<222>(1)...(501)
<400>1
tcactccttc?ttcctgagtc?tgtcttgcag?gtttgtggag?gaagagaagg?ctctcatgac?60
ttctgccctg?acgatctccc?aggcacaggg?gctgtagctc?ttctcttgca?gatagagggt?120
gagtctgtgg?aagtatttcc?tcacagccag?gatggagtcc?tcctccagca?ggggggtccc?180
ttccagcccg?gcctcctgca?tgacacaggc?ttccaggtcc?ctgagctgct?gatccagtcc?240
agtgcagaac?tggtgcagga?ggctctcatc?ccaggcagca?gccgagccct?ctgtgctgaa?300
gagctggaag?gtctgctgga?gcatctcatg?caccagagcc?atggcttgag?ccttctggac?360
ctggttgccc?cccaaggcct?cttgggggaa?tccaaagtcc?cttctgtggt?ccaggcagga?420
gaagggggag?attctcctca?tttgtgccag?gagcctcagg?gccctggtgt?gagccaggct?480
gtgggtctga?ggcaggtcgc?a?501
Claims (7)
1. the preparation method of recombination porcine alpha-type interferon is characterized in that carrying out following steps:
(1), makes up cloning vector
Goal gene is:
TCACTCCTTCTTCCTGAGTCTGTCTTGCAGGTTTGTGGAGGAAGAGAAGGCTCTCATGACTTCTGCCCTGACGATCTCCCAGGCACAGGGGCTGTAGCTCTTCTCTTGCAGATAGAGGGTGAGTCTGTGGAAGTATTTCCTCACAGCCAGGATGGAGTCCTCCTCCAGCAGGGGGGTCCCTTCCAGCCCGGCCTCCTGCATGACACAGGCTTCCAGGTCCCTGAGCTGCTGATCCAGTCCAGTGCAGAACTGGTGCAGGAGGCTCTCATCCCAGGCAGCAGCCGAGCCCTCTGTGCTGAAGAGCTGGAAGGTCTGCTGGAGCATCTCATGCACCAGAGCCATGGCTTGAGCCTTCTGGACCTGGTTGCCCCCCAAGGCCTCTT
GGAATCCAAAGTCCCTTCTGTGGTCCAGGCAGGAGAAGGGGGAGATTCTCCTCATTTGTGCCAGGAGCCTCAGGGCCCTGGTGTGAGCCAGGCTGTGGGTCTGAGGCAGGTCGCA
Auele Specific Primer: upstream: GAATTC TGCGAC CTGCCT CAGACC CA
Downstream: CTCGAG TCACTC CTTCTT CCTGAG TC
Cloning vector: pMD18-T simple vector
(2), construction of expression vector
Expression vector: pET-28a, perhaps pGEX-5X
(3), Recombinant Protein Expression
The recombinant expressed bacterium of picking vector construction success is increased, amplification culture, and adds the expression of inductor low temperature induction;
(4), identify recombinant protein
Use anti-alpha-interferon reference serum and do the neutralization experiment, prove that type is errorless;
(5), purification of recombinant proteins, obtain the raw product Interferon, rabbit.
2. the preparation method of recombination porcine alpha-type interferon according to claim 1 is characterized in that concrete steps are:
(1), makes up cloning vector
Goal gene:
TCACTCCTTCTTCCTGAGTCTGTCTTGCAGGTTTGTGGAGGAAGAGAAGGCTCTCATGACTTCTGCCCTGACGATCTCCCAGGCACAGGGGCTGTAGCTCTTCTCTTGCAGATAGAGGGTGAGTCTGTGGAAGTATTTCCTCACAGCCAGGATGGAGTCCTCCTCCAGCAGGGGGGTCCCTTCCAGCCCGGCCTCCTGCATGACACAGGCTTCCAGGTCCCTGAGCTGCTGATCCAGTCCAGTGCAGAACTGGTGCAGGAGGCTCTCATCCCAGGCAGCAGCCGAGCCCTCTGTGCTGAAGAGCTGGAAGGTCTGCTGGAGCATCTCATGCACCAGAGCCATGGCTTGAGCCTTCTGGACCTGGTTGCCCCCCAAGGCCTCTT
GGGGAATCCAAAGTCCCTTCTGTGGTCCAGGCAGGAGAAGGGGGAGATTCTCCTCATTTGTGCCAGGAGCCTCAGGGCCCTGGTGTGAGCCAGGCTGTGGGTCTGAGGCAGGTCGCA
Specific primer sequence: upstream: GAATTC TGCGAC CTGCCT CAGACC CA
Downstream: CTCGAG TCACTC CTTCTT CCTGAG TC
Behind the goal gene with Auele Specific Primer pcr amplification porcine alpha-type interferon, with goal gene clone in pMD18-T simple vector to and transform the JM109 intestinal bacteria and be coated with the LB culture medium flat plate and carry out the screening of blue hickie, the clone bacterium of extracting waste sample carries out the target gene PCR checking, carrying out double digestion simultaneously identifies, according to experimental result, PCR and the equal positive plasmid of double digestion are carried out objective gene sequencing;
(2), construction of expression vector
After identifying that the back selects the clone bacterium consistent with goal gene to carry out double digestion, be connected, and correspondingly be converted into the BL-21 intestinal bacteria, cultivate respectively, identify the recombinant expressed bacterium of expression vector establishment success with expression vector pET-28a or pGEX-5X;
(3), Recombinant Protein Expression
The recombinant expressed bacterium that is connected with pET-28a or pGEX-5X expression vector of picking carries out a small amount of amplification, amplification culture respectively, adds isopropylthiogalactoside IPTG, and low temperature induction is expressed, and collects bacterium;
(4), identify recombinant protein
Use anti-alpha-interferon reference serum and do the neutralization experiment, prove that type is errorless;
(5), purification of recombinant proteins, obtain the raw product Interferon, rabbit.
3. the preparation method of recombination porcine alpha-type interferon according to claim 1 is characterized in that more detailed steps is:
(1), makes up cloning vector
The goal gene of porcine alpha-type IFN is:
TCACTCCTTCTTCCTGAGTCTGTCTTGCAGGTTTGTGGAGGAAGAGAAGGCTCTCATGACTTCTGCCCTGACGATCTCCCAGGCACAGGGGCTGTAGCTCTTCTCTTGCAGATAGAGGGTGAGTCTGTGGAAGTATTTCCTCACAGCCAGGATGGAGTCCTCCTCCAGCAGGGGGGTCCCTTCCAGCCCGGCCTCCTGCATGACACAGGCTTCCAGGTCCCTGAGCTGCTGATCCAGTCCAGTGCAGAACTGGTGCAGGAGGCTCTCATCCCAGGCAGCAGCCGAGCCCTCTGTGCTGAAGAGCTGGAAGGTCTGCTGGAGCATCTCATGCACCAGAGCCATGGCTTGAGCCTTCTGGACCTGGTTGCCCCCCAAGGCCTCTT
GGGAATCCAAAGTCCCTTCTGTGGTCCAGGCAGGAGAAGGGGGAGATTCTCCTCATTTGTGCCAGGAGCCTCAGGGCCCTGGTGTGAGCCAGGCTGTGGGTCTGAGGCAGGTCGCA
Specific primer sequence: upstream: GAATTC TGCGAC CTGCCT CAGACC CA
Downstream: CTCGAG TCACTC CTTCTT CCTGAG TC
Behind the goal gene with Auele Specific Primer pcr amplification porcine alpha-type IFN, with goal gene clone in pMD18-Tsimple vector to and transform the JM109 intestinal bacteria and be coated with the LB culture medium flat plate and carry out the screening of blue hickie, the clone bacterium of extracting waste sample carries out the target gene PCR checking, carrying out double digestion simultaneously identifies, according to experimental result, PCR and the equal positive plasmid of double digestion are carried out objective gene sequencing;
(2), construction of expression vector
After identifying that the back selects the clone bacterium consistent with goal gene to carry out double digestion, be connected with expression vector pET-28a or pGEX-5X, and correspondingly be converted into the BL-21 intestinal bacteria, separate application is in the LB culture medium flat plate that contains kantlex or contain the LB culture medium flat plate overnight incubation of ammonia benzyl green grass or young crops, get the bacterium colony of growing on the aforementioned flat board and identify goal gene through PCR, the capable double digestion of positive colony bacteria plasmid is identified, is accredited as positive person and represents the expression vector establishment success;
(3), Recombinant Protein Expression
The recombinant expressed bacterium that is connected with pET-28a or pGEX-5X expression vector of picking is in the LB substratum that contains kantlex 100 μ g/ml or contain amplification on a small quantity in the LB substratum of the blue or green 100 μ g/ml of ammonia benzyl respectively, after respectively the LB substratum that contains kantlex 100 μ g/ml or contain in the LB substratum of the blue or green 100 μ g/ml of ammonia benzyl amplification culture or fermentation 3h after, to bacterium arrival logarithmic phase, survey bacterium in the 600nmOD value during at 0.6-0.8, add isopropylthiogalactoside IPTG, 32 ℃ of low temperature inductions are expressed, final concentration 200 μ g/ml collect bacterium;
(4), identify recombinant protein
Use anti-α type IFN reference serum and do the neutralization experiment, prove that type is errorless;
(5), purification of recombinant proteins, obtain raw product IFN.
4. according to the preparation method of one of claim 1-3 described recombination porcine alpha-type interferon, it is characterized in that identifying recombinant protein: with the recombinant plasmid pET-28a/IFN and the pGEX-5X/IFN transformed into escherichia coli BL21 of goal gene, after IPTG induces, intestinal bacteria pET-28a/IFN tropina shows through SDS-PAGE protein electrophoresis and coomassie brilliant blue staining, compare with empty bacterium, a dense newly-increased protein band that dyes is arranged about 25KD; Intestinal bacteria pGEX-5X/IFN tropina shows through SDS-PAGE protein electrophoresis and coomassie brilliant blue staining, compare with empty bacterium, a dense newly-increased protein band that dyes is arranged about 45KD, identify through Western blotting, these two kinds of tropinas all can with anti-α type IFN reference serum generation strong positive reaction.
5. according to the preparation method of one of claim 1-3 described recombination porcine alpha-type interferon, it is characterized in that purification of recombinant proteins is meant with behind the ultrasonication recombinant protein, obtain the solubility recombinant protein in the supernatant, again through the consummate albumen of AKTATMexplorer protein purification instrument affinity chromatography.
6. according to the preparation method of one of claim 1-3 described recombination porcine alpha-type interferon, it is characterized in that: purification of recombinant proteins, the concrete steps that obtain raw product IFN are: collect bacterium liquid, 4 ℃ of centrifugal 5min of 12000r/min, abandon supernatant, stay precipitation ,-20 ℃ with room temperature multigelation precipitation 3 times after will precipitate mixing in 9 times of volume PBS liquid, hatch 5min for 4 ℃, ultrasonic degradation obtains recombinant protein, power: 400W, worked 3 seconds, 3 seconds at interval, ultrasonic 6min repeats 3-4 time, makes gram's staining and observes bacterium cracking situation, the centrifugal 10min of 12000r/min, the results supernatant.
7. the preparation method of recombination porcine alpha-type interferon according to claim 6 is characterized in that: AKTA
TMThe consummate albumen of explorer protein purification instrument affinity chromatography is measured IFN and is tired and specific activity specific activity 〉=1 * 10
6International unit/mg albumen is qualified; Aseptic subpackaged ,-70 ℃ of preservations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100201804A CN101289666B (en) | 2008-03-28 | 2008-03-28 | Method for preparing recombination porcine alpha-type interferon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100201804A CN101289666B (en) | 2008-03-28 | 2008-03-28 | Method for preparing recombination porcine alpha-type interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101289666A CN101289666A (en) | 2008-10-22 |
| CN101289666B true CN101289666B (en) | 2011-10-26 |
Family
ID=40034111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100201804A Active CN101289666B (en) | 2008-03-28 | 2008-03-28 | Method for preparing recombination porcine alpha-type interferon |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101289666B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107326037A (en) * | 2017-07-18 | 2017-11-07 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon beta fusion protein antiviral activity |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101736062B (en) * | 2009-11-27 | 2012-11-07 | 王明丽 | Method for preparing recombinant porcine alpha interferon standard substance |
| CN101845441B (en) * | 2010-03-16 | 2011-10-12 | 南京农业大学 | Composite porcine alpha-IFN gene and recombinant vector thereof |
| CN104262480B (en) * | 2014-09-28 | 2018-03-27 | 重庆理工大学 | The structure and the preparation method of method of modifying and its freeze dried injection of the long-acting alpha interferon of Recombinant Swine |
| CN105755008A (en) * | 2014-12-17 | 2016-07-13 | 北京大北农科技集团股份有限公司动物医学研究中心 | DNA molecule for coding porcine alpha interferon and expression and purification method of recombinant protein of porcine alpha interferon |
| CN106939042B (en) * | 2016-01-22 | 2020-12-15 | 华南农业大学 | Porcine alpha interferon and application thereof |
| CN106892976A (en) * | 2017-02-14 | 2017-06-27 | 华南农业大学 | A kind of recombination chicken interferon lambda（rChIFN‑λ）Clonal expression of gene and its preparation method and application |
-
2008
- 2008-03-28 CN CN2008100201804A patent/CN101289666B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107326037A (en) * | 2017-07-18 | 2017-11-07 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon beta fusion protein antiviral activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101289666A (en) | 2008-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101289666B (en) | Method for preparing recombination porcine alpha-type interferon | |
| CN106282216B (en) | A kind of preparation method of recombinant long-acting chicken interferon α | |
| Huang et al. | Functions of TNF-α1 and TNF-α2 in large yellow croaker (Larimichthys crocea) in monocyte/macrophage activation | |
| CN105176874B (en) | Bacillus coagulans FM603 and its application | |
| CN105175518B (en) | The bacteriocin and preparation method thereof that bacillus coagulans FM603 is generated | |
| CN101340927A (en) | Application of TGF-beta1 inhibitory polypeptide on immune response modifier preparation | |
| CN104447978A (en) | Recombinant chicken interferon alpha and preparation method thereof | |
| Gao et al. | Newcastle disease virus RNA-induced IL-1β expression via the NLRP3/caspase-1 inflammasome | |
| CN103290021A (en) | A preparation method for recombinant chicken interferon alpha | |
| CN104498441A (en) | Duck hepatitis A virus III type attenuated strain, live vaccine prepared from same and application of live vaccine | |
| CN103936862A (en) | Co-expression of fusion porcine interleukin 4/6 and interleukin 2 genes and application of fusion porcine interleukin 4/6,2 gene in preparation of biological agents | |
| CN101100664B (en) | Method for preparing recombinant canine alpha-type interferon | |
| CN104805066A (en) | Staphylococcus lyase and application thereof | |
| CN111729091B (en) | Method for checking efficacy of porcine Seika virus inactivated vaccine by using rabbit | |
| CN105647970A (en) | Prostate-cancer-specific PAP (prostatic acid phosphatase)-GM-CSF (granulocyte-macrophage colony-stimulating factor)-IL-6 (interluekin-6) genetic recombinant fusion protein and preparation method thereof | |
| CN102199215B (en) | MAPWA fusion antibacterial peptide, preparation method and application thereof | |
| CN104531690A (en) | Primers for obtaining genes of sheep interferon tau and preparation method for recombinant sheep interferon tau | |
| CN109797139A (en) | 3 type duck hepatitis A virus low virulent strain CH-P60 of one kind and its application | |
| CN110357971B (en) | Pig compound interferon for emergency prevention of African swine fever | |
| CN102229944B (en) | Method for preparing recombinant porcine alpha-interferon | |
| CN106119221A (en) | Phosphatidylinositol-specific phospholipase C gene, carrier, engineering bacteria and application | |
| CN104531691A (en) | Primers for obtaining genes of bovine interferon alpha and preparation method for recombinant bovine interferon alpha | |
| CN106518997B (en) | A kind of clarias leather antibacterial peptide and extracting method | |
| CN105132497A (en) | Preparation process of recombinant poultry interferon alpha product lyophilized preparation | |
| CN102690884B (en) | Gene engineering preparation for detecting bovine mycobacterium infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ANHUI JIUCHUAN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WANG MINGLI Effective date: 20120509 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 230032 HEFEI, ANHUI PROVINCE TO: 241009 WUHU, ANHUI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120509 Address after: 241009 Anhui city of Wuhu Province Branch Center D Park Economic and Technological Development Zone No. 102, 101 Patentee after: Anhui JiuChuan Biotechnology Co., Ltd. Address before: 230032 Department of Microbiology, Medical University Of Anhui, 81 Mei Shan Road, Anhui, Hefei Patentee before: Wang Mingli |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160224 Address after: 241009 Anhui city of Wuhu Province Branch Center D Park Economic and Technological Development Zone No. 102, 101 Patentee after: Anhui JiuChuan Biotechnology Co., Ltd. Patentee after: Wuhu Phil Biological Products Industry Research Institute Co. Ltd. Address before: 241009 Anhui city of Wuhu Province Branch Center D Park Economic and Technological Development Zone No. 102, 101 Patentee before: Anhui JiuChuan Biotechnology Co., Ltd. |